Pegylated-interferon-α2a in clinical practice: How to manage patients suffering from side effects

Expert Opinion on Drug Safety

Volumn 10, Issue 3, 2011, Pages 429-435

  Calvaruso, Vincenza ^a   Mazza, Marta ^a   Almasio, Piero L ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

HCV; PEG IFN; ribavirin; side effects

Indexed keywords

ELTROMBOPAG; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; IBUPROFEN; LORATADINE; MINOXIDIL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARACETAMOL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR;

ADVERSE DRUG REACTION; ALOPECIA; ALOPECIA AREATA; ANEMIA; ARTHRALGIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLURRED VISION; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; COLOR VISION; COTTON WOOL SPOT; COUGHING; DEPRESSION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; EYE DISEASE; FLU LIKE SYNDROME; GLAUCOMA; GRAVES DISEASE; HAIR LOSS; HASHIMOTO DISEASE; HEARING LOSS; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INTERSTITIAL PNEUMONIA; LEUKOCYTOCLASTIC VASCULITIS; LICHEN PLANUS; MENTAL DISEASE; MYALGIA; NEUTROPENIA; NEUTROPHIL COUNT; OPTIC NERVE DISEASE; OPTIC NEURITIS; OTOTOXICITY; PAINLESS THYROIDITIS; POLYARTERITIS NODOSA; PORPHYRIA CUTANEA TARDA; PURE RED CELL ANEMIA; RESPIRATORY TRACT DISEASE; RETINA ARTERY OCCLUSION; RETINA HEMORRHAGE; RETINA VEIN OCCLUSION; REVIEW; RISK FACTOR; SCREENING; SIDE EFFECT; SKIN DISEASE; SKIN NODULE; SKIN ULCER; THROMBOCYTOPENIA; URTICARIA;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MEDICATION THERAPY MANAGEMENT; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 79955407482     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.559161     Document Type: Review

References (61)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436-41 (Pubitemid 46929498)
2. Oh S, Afdhal NM. Antiviral therapy for treatment naive patients with hepatitis C virus. Gastroenterol Clin N Am 2004;33:497-511 (Pubitemid 39485895)
3. Fried MW, Shiffman ML, Reddy KR, et al. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65 (Pubitemid 32913521)
5. Fried MW. Side effects of therapy for hepatitis C and their management. Hepatology 2002;36:S237-44 (Pubitemid 35253486)
6. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346
7. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997-1004 (Pubitemid 30169949)
8. Homma M, Matsuzaki Y, Inoue Y, et al. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2004;2:337-9 (Pubitemid 38447199)
9. Canonico PG, Kastello MD, Spears CT, et al. Effects of ribavirin on red blood cells. Toxicol Appl Pharmacol 1984;74:155-62 (Pubitemid 14083681)
10. Cosgriff TM, Hodgson LA, Canonico PG, et al. Morphological alterations in blood and bone marrow of ribavirin-treated monkeys. Acta Haematol 1984;72:195-200 (Pubitemid 15208194)
11. Srinivasan R. Autoimmune hemolytic anemia in treatment-naive chronic hepatitis C infection. J Clin Gastroenterol 2001;32:245-7 (Pubitemid 32174120)
12. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002;123:141-51 (Pubitemid 34747535)
13. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-9 (Pubitemid 35253446)
14. Higashi Y, Sakai K, Tada S, et al. Case report: agranulocytosis induced by interferon alpha therapy for chronic hepatitis C. J Gastroenterol Hepatol 1996;11:1012-15 (Pubitemid 26396236)
15. Van Thiel DH, Faruki H, Friedlander L, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995;42:907-12 (Pubitemid 26026454)
16. Fukuda A, Kobayashi H, Teramura K, et al. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. Cytokines Cell Mol Ther 2000;6:149-54 (Pubitemid 32098588)
17. Carreno V, Martin J, Pardo M, et al. Randomized controlled trial of recombinant human granulocyte-macrophage colonystimulating factor for the treatment of chronic hepatitis C. Cytokine 2000;12:165-70 (Pubitemid 30449871)
18. Shiffman ML, Hofmann CM, Luketic VA, Sanyal AJ. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. J Hepatol 1998;28:382-9 (Pubitemid 28133540)
19. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of hypersplenic thrombocytopenia. J Clin Invest 1966;45:645-57
20. Kawasaki T, Takeshita A, Souda K, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999;94:1918-22 (Pubitemid 29315911)
21. Yagura M, Tanaka A, Tokita H, et al. Factors regarding increase of platelet counts in chronic hepatitis C patients with sustained virological response to interferon-Relation to serum thrombopoietin levels. Hepatol Res 2005;33:211-15 (Pubitemid 41794209)
22. Danish FA, Koul SS, Subhani FR, et al. Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag. Saudi J Gastroenterol 2010;16:51-6
23. Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207-11 (Pubitemid 30351279)
24. Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000;18:107-16 (Pubitemid 32250153)
25. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22:86-90 (Pubitemid 34101297)
26. Farkkila M, Iivanainen M, Harkonen M, et al. Effect of interferon-gamma on biogenic amine metabolism, electroencephalographic recordings, and transient potentials. Clin Neuropharmacol 1988;11:63-7 (Pubitemid 18040466)
27. Bonaccorso S, Puzella A, Marino V, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001;105:45-55 (Pubitemid 34015882)
28. Juengling FD, Ebert D, Gut O, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) 2000;152:383-9
29. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37:443-51 (Pubitemid 36152544)
30. Kraus MR, Schafer A, Csef H, et al. Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Dig Dis Sci 2001;46:2060-5 (Pubitemid 32955211)
31. Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-9 (Pubitemid 34680751)
32. Epstein SA. Psychotropic medications in gastrointestinal and hepatic disease. Adv Psychosom Med 1994;21:49-60
33. Diez-Quevedo C, Masnou H, Planas R, et al. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis c: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010. [Epub ahead of print]
34. Kumar KS, Russo MW, Borczuk AC, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002;97:2432-40
35. Ogata K, Koga T, Yagawa K. Interferon-related bronchiolitis obliterans organizing pneumonia. Chest 1994;106:612-13 (Pubitemid 24252073)
36. Perez-Alvarez R, Perez-Lopez R, Lombrana JL, et al. Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine. J Viral Hepat 2002;9:75-9
37. Hoffmann RM, Jung MC, Motz R, et al. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J Hepatol 1998;28:1058-63 (Pubitemid 28275987)
38. Rothfuss KS, Bode JC. Interstitial pneumonitis during combination therapy with interferon-alpha and ribavirin in a patient with chronic Hepatitis C. Z Gastroenterol 2002;40:807-10
39. Karim A, Ahmed S, Khan A, et al. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection. Am J Med Sci 2001;322:233-5 (Pubitemid 32973277)
40. Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996;91:309-13 (Pubitemid 26067340)
41. Sene D, Touitou V, Bodaghi B, et al. Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol 2007;13:3137-40 (Pubitemid 47045476)
42. Kwon YS, Choe YH, Chin HS. Development of glaucoma in the course of interferon alpha therapy for chronic hepatitis B. Yonsei Med J 2001;42:134-6
43. Manesis EK, Moschos M, Brouzas D, et al. Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology 1998;27:1421-7 (Pubitemid 28227873)
44. Fortin E. Neurovisual complications of interferon-alpha therapy. Hepatology 1998;27:1441-2
45. Huang MJ, Tsai SL, Huang BY, et al. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol (Oxf) 1999;50:503-9
46. Carella C, Mazziotti G, Morisco F, et al. Long-term outcome of interferon alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001;86:1925-9 (Pubitemid 32472899)
47. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996;44:635-42 (Pubitemid 26225178)
48. Watanabe U, Hashimoto E, Hisamitsu T, et al. The risk factor for development of thyroid disease during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994;89:399-403 (Pubitemid 24074402)
49. Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997;26:206-10 (Pubitemid 27280326)
50. Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993;18:253-7 (Pubitemid 23225092)
51. Noto H, Raskin P. Hepatitis C infection and diabetes. J Diabetes Complications 2006;20:113-20
52. Georgetson MJ, Yarze JC, Lalos AT, et al. Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. Am J Gastroenterol 1993;88:1756-8 (Pubitemid 23298128)
53. Simsek H, Savas C, Akkiz H, Telatar H. Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Dermatology 1996;193:65-6 (Pubitemid 26257102)
54. Nagao Y, Sata M, Ide T, et al. Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C. Eur J Clin Invest 1996;26:1171-4 (Pubitemid 27023537)
55. Borghi-Scoazec G, Merle P, Scoazec JY, et al. Onset of dermatitis herpetiformis after treatment by interferon and ribavirin for chronic hepatitis C. J Hepatol 2004;40:871-2 (Pubitemid 38507374)
56. Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 2007;19:817-20 (Pubitemid 47266714)
57. Shafa S, Borum ML, Igiehon E. A case of irreversible alopecia associated with ribavirin and peg-interferon therapy. Eur J Gastroenterol Hepatol 2010;22:122-3
58. Kernland KH, Hunziker T. Alopecia areata induced by interferon alpha? Dermatology 1999;198:418-19 (Pubitemid 29335745)
59. Formann E, Stauber R, Denk DM, et al. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol 2004;99:873-7 (Pubitemid 39090216)
60. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38
61. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-16